ReviewFrontiers in immunology2021
The Fate of Activated Group 2 Innate Lymphoid Cells.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Alterations of circulating innate lymphoid cells in recent-onset type 1 diabetes.Clinical & translational immunology · 2026Article
- Engineered Neuromedin U Promotes Type 2 Innate Immunity and Renoprotection in Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025Article
- Allergen-Specific Immunotherapy and Trained Immunity.Allergy · 2025Review
- Innate lymphoid cells in bone marrow and peripheral blood of healthy individuals and in bone marrow of patients with myelodysplastic syndromes.Frontiers in immunology · 2025Article
- Review
- A novel type-2 innate lymphoid cell-based immunotherapy for cancer.Frontiers in immunology · 2024Article
- Hypothesis: hematogenous metastatic cancer cells of solid tumors may disguise themselves as memory macrophages for metastasis.Frontiers in oncology · 2024Article
- Overview of the development, characterization, and function of human types 1, 2, and 3 innate lymphoid cells.Einstein (Sao Paulo, Brazil) · 2024Review
- Fungal Aeroallergens-The Impact of Climate Change.Journal of fungi (Basel, Switzerland) · 2023Review
- How to train your myeloid cells: a way forward for helminth vaccines?Frontiers in immunology · 2023Review
- Flow cytometric analysis of innate lymphoid cells: challenges and solutions.Frontiers in immunology · 2023Review
- Innate lymphoid cells in early tumor development.Frontiers in immunology · 2022Review
- Interleukin 25 and its biological features and function in intestinal diseases.Central-European journal of immunology · 2022Review
- Interleukin-33: Metabolic checkpoints, metabolic processes, and epigenetic regulation in immune cells.Frontiers in immunology · 2022Review
- Stem Cell Therapy and Innate Lymphoid Cells.Stem cells international · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Group 2 innate lymphoid cells (ILC2s) reside in both mucosal and non-mucosal tissues and play critical roles in the first line of defense against parasites and irritants such as allergens. Upon activation by cytokines released from epithelial and stromal cells during tissue damage or stimulation, ILC2s produce copious amounts of IL-5 and IL-13, leading to type 2 inflammation. Over the past 10 years, ILC2 involvement in a variety of human diseases has been unveiled. However, questions remain as to the fate of ILC2s after activation and how that might impact their role in chronic inflammatory diseases such as asthma and fibrosis. Here, we review studies that have revealed novel properties of post-activation ILC2s including the generation of immunological memory, exhausted-like phenotype, transdifferentiation and activation-induced migration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.